We are global experts in access for orphan drugs,
cell and gene therapies. We believe in making a difference to those involved in rare diseases

Why we do what we do

At P4A, we believe in striking an equilibrium in the orphan drug,
cell and gene therapy world. That means helping drive access to the
most appropriate treatments for patients and physicians, a fair return
on investment for manufacturers at an affordable proposition for payers

Driving Access

Safeguarding manufacturers

Affordable and fair outcomes

Our History

2015

P4A is established in Dec 2015 as a BV (Limited Company) in the Netherlands. Vertex becomes its first official customer.

Interesting fact: Vertex was a key inspiration in focusing solely on rare disease companies when founder, Sophie Schmitz, worked with the team supporting the original Kalydeco strategy.

2015

2016

P4A sets up roots with a partnership in the US and establishes an office in London as the European HQ. P4A also supports its first gene therapy company develop their price and access strategy.

2016

2017

P4A begins to firmly establish itself as an expert in gene therapy, presenting in various forums across the world at AMCP, WODC and several online events.

2017

2018

P4A formalizes its Payer Expert Network supporting clients with informal and formal advice from payers across the world. 

2018

2019

XINTA, our analog intelligence engine is developed from our in-house expertise and knowledge.

2019

2020

P4A wins Best Specialist Biotech Market Access Consultancy Award and continues to spread its roots throughout the EU, developing bases in Germany and Poland.

2020

When you work with P4A
you are getting the best

Our staff are carefully recruited and passionate about the Rare Disease world. 
We are motivated by working in partnership with clients who share our vision
in creating and maintaining fair and sustainable healthcare systems for all stakeholders

Pride, passion and partnership are the core values at P4A. We
partner with our clients globally to achieve optimal patient access.